Role of TRAIL in the treatment of prostate cancer: An update.
- Author:
Ji-ci MA
;
Qing-chuan ZHANG
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Apoptosis;
Apoptosis Regulatory Proteins;
Humans;
Male;
Membrane Glycoproteins;
Prostatic Neoplasms;
drug therapy;
pathology;
Receptors, TNF-Related Apoptosis-Inducing Ligand;
physiology;
therapeutic use;
TNF-Related Apoptosis-Inducing Ligand;
Tumor Necrosis Factor-alpha
- From:
National Journal of Andrology
2015;21(10):941-944
- CountryChina
- Language:Chinese
-
Abstract:
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF super family found in recent years, which widely exists in the body tissues and participates in the immune regulation, immune stability, and immune surveillance of the human body. The TRAIL receptor is expressed in the surface of a variety of cells. Recent studies show that TRAIL induces the apoptosis of tumor cells and has no significant toxic effect on normal cells. Its anti-tumor activity and safety have been widely recognized. The development of prostate cancer is regulated by the mechanisms of cell apoptosis. TRAIL can induce the apoptosis of prostate cancer cells, and therefore has a great application value in the treatment of prostate cancer.
